Table 4.

Outcome (survival) analysis

Median follow-up	20 months (17-51)
Progression	1 (3.7%)
LR recurrence	3 (10.7%)
Lung metastasis	4 (14.9%)
Liver metastasis	1 (3.7%)
Over all RR (5 yr)	75% (BT boost: 83.3%/radical BT: 76.2%)
Local control (5 yr)	85.7% (BT boost: 90.5%/radical BT: 83.2%)
Survival (months)	Mean ± SE (95% CI)
LRFFS	43.8 ±3.6 (36.8-50.9)
DFS	39.7 ±3.9 (32-47.2)
Distant FFS	21.5 ±2.7 (15.9-26.6) Median 18 (15.5-26.6)
OS	42.4 ±3.4 (35.7-48.1)

RR – response rate; SE – standard error of mean; LRFFS – loco-regional failure-free survival; DFS – disease-free survival; distant FFS – distant failure-free survival; OS – overall survival; yr – years